Skip to main content
OpenTrials
Completed

NCT Number: NCT06739772

Development of Implementation Toolkits

The purpose of the study is to conduct an intervention program aimed at increasing HPV self-sampling among women living with HIV in Ghana.

Completed

Looking for future studies?

Notify Me

Key information

Age range

25 year–65 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

University of Cape Coast Teaching Hospital

Cape Coast, Central Region, Ghana

About this study

Women living with HIV, (WLWH), in low- and middle-income countries (LMICs) have a six-fold increased risk of developing cervical cancer (CC) compared to their uninfected counterparts. Our studies in Ghana show that self-sampling is acceptable, easy to use, and efficacious in detecting precancer lesions among WLWH. However, this screening mechanism has not been translated to healthcare practice in Ghana.

Systematic adaptation and implementation toolkits are needed to translate self-sampling into healthcare practices. We develop a Home-based self-collected sampling for the cervical cancer Prevention Education (HOPE) toolkits to promote cervical cancer screening in Ghana. HOPE toolkit core components such as (a) self-sample HPV testing kits and (b) the 3R (Reframe, Reprioritize, and Reform) communication model will not change as they are evidence-based. The content and the intervention delivery modalities of HOPE will go through the cultural adaptation iterative processes.

This R21 resubmission seeks to develop contextually appropriate adaptation and implementation toolkits in Ghana. A three-step approach will be used for the adaption process and evaluation of the toolkit. First, we will organize focus group discussions (FGDs) to identify contextual factors affecting the toolkit adaptation and nominal group techniques (NGTs) to determine the different compositions of the toolkits and select the final toolkit. A sample of 35 stakeholder advisory board members representing three organizational levels: potential intervention participants (i.e., WLWH), community leaders, and healthcare workers (e.g., doctors, nurses, administrators) will participate in the focus group FGDs and NGTs. Second, we will recruit 45 participants including WLWH and healthcare workers to evaluate the feasibility, acceptability, appropriateness, and adoptability of the selected toolkit. Third, we will test the preliminary efficacy of HOPE on cervical cancer screening defined as cervical cancer screening uptake among WLWH in the intervention arm (n=54) and control arm (n = 54). Participants will be recruited from the Cape Coast Teaching Hospital (CCTH). Specific aims of HOPE are:

Aim I: Develop and adapt the HOPE toolkit: Hypothesis: Stakeholders will identify and prioritize community needs and translate findings into a culturally adapted toolkit. Aim II: Evaluate the characteristics of the HOPE toolkit: Hypothesis: We hypothesize that 80% of participants will find HOPE toolkits feasible, acceptable, appropriate, and adoptable. Aim III: Assess the efficacy of HOPE on CCS. Hypothesis: We hypothesize that CCS behavior will increase significantly among women in the intervention group compared to those in the control group. Aim IV: Identify actionable factors and implementation costs that influence the adoption of the toolkit. Hypothesis: The Actionable factors and implementation costs will significantly influence the toolkit adoption.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • General eligibility criteria for these stakeholders include (1) the ability to give consent per Institutional Review Board stipulations, (2) residing in the central region of Ghana, (3) having no medical, psychological, or social characteristics that would interfere with the ability to fully participate, and (4) the willingness to participate in this study.
  • Specific eligibility for Intervention participants (WLWH). Study inclusion/exclusion criteria for potential participants will be assessed using E-tracker data and include women (identified female at birth) who (1) are living with HIV between 25 and 65 years old5 and (2) have never had a cervical cancer screening like pap test or HPV test before, or have not had pap test or HPV testing for the past 5 years

Exclusion criteria

  • Women will be excluded if they are pregnant or have had a hysterectomy. WLWH (female-identified at birth) who have a cervix are the main target population to develop the HOPE toolkit.

Treatment and study plan

HPV Self-Sampling and Behavior Intervention

Behavioral

Participants in the intervention group will receive HPV self sampling and behavioral intervention

Participants in the intervention group will receive HPV self sampling and behavioral intervention

Behavioral

Received enhance standard care

Primary outcomes

  1. Cervical cancer screening uptake

    Time frame: 6 weeks

    The outcome is screening uptake (i.e., the completion and return of a self-sample kit and pap test completion). Measure: The screening completion outcome will be binary (yes/no), and it will be assessed via the patient clinical records by the doctors at 6 weeks post-intervention. The screening completion outcome will be binary (yes/no)

Secondary outcomes

  1. Screening Test Results

    Time frame: 6 weeks

    Screening test results (positive, negative, or inadequate). Measure: The screening test results (positive, negative, or inadequate), will be treated as categorical outcome and it will be assessed via the patient clinical records by the doctors at 6 weeks post-intervention.

  2. Treatment follow-up

    Time frame: 6 weeks

    Whether patients with positive results follow up for treatment or not. Measures: The outcomes will be assessed via the patient clinical records by the doctors at 6 weeks post-intervention. The treatment follow-up (yes, no, or lost-to-follow-up) will be treated as categorical outcomes

Other outcomes

  1. Actionable outcome : Implementation experience

    Time frame: 6 weeks after the intervention

    Implementation experience, including resource availability, managerial support, and technical issues confronted. Measure: Following the completion of the intervention(i.e., after 6 weeks), interviews will be conducted among healthcare providers using a semi-structured interview guide to assess the implementation experience outcome.

  2. Actionable factor: Operational experience

    Time frame: 6 weeks after the intervention

    Operational experience, including workload increase or decrease, the flow of communication in the hospital, and any skills needed. Measure: Following the completion of the intervention(i.e., after 6 weeks), interviews will be conducted among healthcare providers using a semi-structured interview guide to assess the operational experience outcome.

  3. Actionable factor: Adoption or level of endorsement

    Time frame: 6 weeks after the intervention

    Level of endorsement of the toolkit adoption and recommendations for maintenance. Measure: Following the completion of the intervention(i.e., after 6 weeks), interviews will be conducted among healthcare providers using a semi-structured interview guide to assess the adoption or endorsement outcome.

  4. Implementation cost

    Time frame: Throughout the intervention period (about 12 months)

    Implementation costs will include (i) sampling materials, including kits and laboratory testing costs; (ii) recruitment (i.e., time spent identifying and contacting eligible women, advertising materials, participant incentives); (iii) intervention delivery; (iv) participant out-of-pocket costs (e.g., transportation, childcare, mobile data usage, time spent on the intervention); (v) clinic-based Pap tests; and (vi) treatment and biopsies. Measure: A cost-tracking database will be used throughout the study to itemize, quantify, and value the resources.

Sponsors and collaborators

Lead sponsor

Baylor University

Other

Registry information

Official study title

Development of Implementation Toolkits to Promote HPV Self-sampling Behavior Among Women Living With HIV in Ghana

Acronym: HOPE

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Dec 18, 2024
Registry last updated
Apr 29, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.